TP53 GENE MUTATION
Clinical trials for TP53 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new TP53 GENE MUTATION trials appear
Sign up with your email to follow new studies for TP53 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Not yet recruitingThis study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…
Matched conditions: TP53 GENE MUTATION
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for Hard-to-Treat leukemia? early trial combines three drugs
Disease control Not yet recruitingThis early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how …
Matched conditions: TP53 GENE MUTATION
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC